中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2014年
22期
10-12
,共3页
艾塞那肽%二甲双胍%2型糖尿病%临床疗效%安全性
艾塞那肽%二甲雙胍%2型糖尿病%臨床療效%安全性
애새나태%이갑쌍고%2형당뇨병%림상료효%안전성
Exenatide%Metformin%Type 2 diabetes mellitus%Clinical efficacy%Safety
目的：观察和探讨艾塞那肽联合二甲双胍治疗2型糖尿病的临床疗效性和安全性。方法：2011年6月-2013年6月就诊于笔者所在医院的2型糖尿病患者67例作为观察组，观察组患者给予艾塞那肽联合二甲双胍进行治疗，同时入选同期于笔者所在医院治疗的2型糖尿病患者34例作为对照组，对照组患者给予瑞格列奈治疗，对两组患者的临床疗效性和安全性进行对比研究。结果：治疗16周后观察组降糖达标率上升至62.69%，对照组上升至50.00%，两组比较差异有统计学意义(P<0.05)；治疗后FPG、HbA1c及BMI方面观察组对比对照组均有显著降低(P<0.05)，观察组对比对照组2 h PBG方面虽有明显降低，但差异无统计学意义(P>0.05)；观察组对比对照组血脂、C肽指标方面治疗后差异有统计学意义(P<0.05)；观察组不良反应发生率为4.48%，对照组为11.76%，两组比较差异有统计学意义(P<0.05)，两组患者不良反应经停药及对症治疗均好转消失，未造成不良后果。结论：艾塞那肽能够持续有效控制2型糖尿病患者血糖情况，与二甲双胍联合应用降糖效果显著，同时有降低患者体质量的优势，改善患者内分泌指标，减低低血糖发生风险，可以成为临床上治疗2型糖尿病的较好选择，值得临床推广应用。
目的：觀察和探討艾塞那肽聯閤二甲雙胍治療2型糖尿病的臨床療效性和安全性。方法：2011年6月-2013年6月就診于筆者所在醫院的2型糖尿病患者67例作為觀察組，觀察組患者給予艾塞那肽聯閤二甲雙胍進行治療，同時入選同期于筆者所在醫院治療的2型糖尿病患者34例作為對照組，對照組患者給予瑞格列奈治療，對兩組患者的臨床療效性和安全性進行對比研究。結果：治療16週後觀察組降糖達標率上升至62.69%，對照組上升至50.00%，兩組比較差異有統計學意義(P<0.05)；治療後FPG、HbA1c及BMI方麵觀察組對比對照組均有顯著降低(P<0.05)，觀察組對比對照組2 h PBG方麵雖有明顯降低，但差異無統計學意義(P>0.05)；觀察組對比對照組血脂、C肽指標方麵治療後差異有統計學意義(P<0.05)；觀察組不良反應髮生率為4.48%，對照組為11.76%，兩組比較差異有統計學意義(P<0.05)，兩組患者不良反應經停藥及對癥治療均好轉消失，未造成不良後果。結論：艾塞那肽能夠持續有效控製2型糖尿病患者血糖情況，與二甲雙胍聯閤應用降糖效果顯著，同時有降低患者體質量的優勢，改善患者內分泌指標，減低低血糖髮生風險，可以成為臨床上治療2型糖尿病的較好選擇，值得臨床推廣應用。
목적：관찰화탐토애새나태연합이갑쌍고치료2형당뇨병적림상료효성화안전성。방법：2011년6월-2013년6월취진우필자소재의원적2형당뇨병환자67례작위관찰조，관찰조환자급여애새나태연합이갑쌍고진행치료，동시입선동기우필자소재의원치료적2형당뇨병환자34례작위대조조，대조조환자급여서격렬내치료，대량조환자적림상료효성화안전성진행대비연구。결과：치료16주후관찰조강당체표솔상승지62.69%，대조조상승지50.00%，량조비교차이유통계학의의(P<0.05)；치료후FPG、HbA1c급BMI방면관찰조대비대조조균유현저강저(P<0.05)，관찰조대비대조조2 h PBG방면수유명현강저，단차이무통계학의의(P>0.05)；관찰조대비대조조혈지、C태지표방면치료후차이유통계학의의(P<0.05)；관찰조불량반응발생솔위4.48%，대조조위11.76%，량조비교차이유통계학의의(P<0.05)，량조환자불량반응경정약급대증치료균호전소실，미조성불량후과。결론：애새나태능구지속유효공제2형당뇨병환자혈당정황，여이갑쌍고연합응용강당효과현저，동시유강저환자체질량적우세，개선환자내분비지표，감저저혈당발생풍험，가이성위림상상치료2형당뇨병적교호선택，치득림상추엄응용。
Objective:To investigate the clinical efficacy and safety of Exenatide combined with Metformin in the treatment of type 2 diabetes mellitus. Method:67 cases with type 2 diabetes mellitus in our hospital from June 2011 to June 2013 were considered as the observation group and another 34 cases were considered as the control group.The observation group was treated with Exenatide and Metformin,while the control group was treated with Repaglinide.Comparing the clinical efficacy and safety of two groups.Result:16 weeks after the treatment,the observation group hypoglycemic compliance rate rose to 62.69%,the control group rose to 50.00%(P<0.05).After treatment,FPG,HbA1c and BMI in the observation group compared with the control group decreased significantly,P<0.05).The observation group compared with the control group in 2 h PBG was significantly reduced,but the difference was not statistically significant(P>0.05). The observation group compared with the control group,there were significant differences in serum lipids and C peptide index after treatment(P<0.05),the observation group can significantly reduce blood lipids,and elevated serum C peptide index compared with the control group.The incidence of adverse reaction in observation group was 4.48%,the control group was 11.76%,there was no significant difference between two groups(P>0.05).Adverse reactios of two groups with drug withdrawal and symptomatic treatment were improved and disappeared,did not cause adverse consequences.Conclusion:Exenatide can continuously and effectively control blood glucose in type 2 diabetes mellitus.The combined application of exenatide and metformin could reduce patients’ body weight,improve endocrine indexes of patients and reduce the risk of hypoglycemia,it could be considered as a good choice in treatment of type 2 diabetes mellitus,is worthy of clinical application.
